Determinants of Response to Insulin Therapy Following Failure of Oral Agents in Type 2 Diabetes
- Janaka Karalliedde, MRCP,
- Andy Smith, MRCP and
- Giancarlo Viberti, MD, FRCP
- Department of Endocrinology, Diabetes and Internal Medicine, King's College London, Guy's Hospital, London, U.K
- Address correspondence to Dr. J. Karalliedde, Department of Endocrinology, Diabetes and Internal Medicine, King's College London, 5th Floor Thomas Guy House, Guy's Hospital, London SE1 9RT, U.K. E-mail: j.karalliedde{at}kcl.ac.uk
Obesity, ethnicity, and concomitant metformin therapy may modify the metabolic response to insulin in patients with type 2 diabetes (1–3). We performed a retrospective case note analysis of 280 type 2 diabetic patients who had failed oral drug therapy, defined as HbA1c (A1C) >7.5% for at least 6 months despite maximum doses of sulfonylurea and metformin, and received treatment with exogenous insulin for at least 12 months for indications other than pregnancy, …
